| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A A Koris. The antidiabetic action of camel milk in experimental type 2 diabetes mellitus: an overview on the changes in incretin hormones, insulin resistance, and inflammatory cytokines. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 46. issue 6. 2015-01-21. PMID:24627103. |
the changes in glucagon like peptide-1 (glp-1), glucose dependent insulinotropic peptide (gip), glucose tolerance, fasting and glucose-stimulated insulin secretion, insulin resistance (ir), tnf-α, tgf-β1, lipid profile, atherogenic index (ai), and body weight were investigated. |
2015-01-21 |
2023-08-12 |
rat |
| David J Hodson, Andrei I Tarasov, Silvia Gimeno Brias, Ryan K Mitchell, Natalie R Johnston, Shahab Haghollahi, Matthew C Cane, Marco Bugliani, Piero Marchetti, Domenico Bosco, Paul R Johnson, Stephen J Hughes, Guy A Rutte. Incretin-modulated beta cell energetics in intact islets of Langerhans. Molecular endocrinology (Baltimore, Md.). vol 28. issue 6. 2015-01-20. PMID:24766140. |
incretins such as glucagon-like peptide 1 (glp-1) are released from the gut and potentiate insulin release in a glucose-dependent manner. |
2015-01-20 |
2023-08-13 |
mouse |
| Tricia M Tan, Victoria Salem, Rachel C Troke, Ali Alsafi, Benjamin C T Field, Akila De Silva, Shivani Misra, Kevin C R Baynes, Mandy Donaldson, James Minnion, Mohammad A Ghatei, Ian F Godsland, Stephen R Bloo. Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose. The Journal of clinical endocrinology and metabolism. vol 99. issue 11. 2015-01-16. PMID:25144632. |
combination of peptide yy3-36 with glp-1(7-36) amide causes an increase in first-phase insulin secretion after iv glucose. |
2015-01-16 |
2023-08-13 |
Not clear |
| B Ma, X Hu, X Zhao, Y Zhang, C Li, Z Ma, S A Abbas, W Chen, S Qu, M L. Pharmacokinetics, pharmacodynamics, and cytotoxicity of recombinant orally-administrated long-lasting GLP-1 and its therapeutic effect on db/db mice. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 122. issue 4. 2015-01-15. PMID:24771009. |
recombinant orally long-acting glucagon-like peptide 1 (rolglp-1), a novel analog of native glp-1 that can stimulate insulin secretion, was constructed via site-directed mutagenesis by our laboratory. |
2015-01-15 |
2023-08-13 |
mouse |
| Natalie A Terry, Erik R Walp, Randall A Lee, Klaus H Kaestner, Catherine Lee Ma. Impaired enteroendocrine development in intestinal-specific Islet1 mouse mutants causes impaired glucose homeostasis. American journal of physiology. Gastrointestinal and liver physiology. vol 307. issue 10. 2015-01-15. PMID:25214396. |
furthermore, enteroendocrine cells regulate glucose metabolism, with the incretin hormones glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) playing critical roles in stimulating insulin release by pancreatic β-cells. |
2015-01-15 |
2023-08-13 |
mouse |
| Philip A Levin, Wenhui Wei, Steve Zhou, Lin Xie, Onur Base. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes. Journal of managed care & specialty pharmacy. vol 20. issue 5. 2015-01-14. PMID:24761822. |
patients with uncontrolled type 2 diabetes mellitus (t2dm), despite therapy with 2 oral antidiabetic drugs (oads), may add a third oad or a glucagon-like peptide-1 receptor agonist (glp-1) or initiate insulin therapy. |
2015-01-14 |
2023-08-13 |
Not clear |
| Fares Bassil, Pierre-Olivier Fernagut, Erwan Bezard, Wassilios G Meissne. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Progress in neurobiology. vol 118. 2015-01-12. PMID:24582776. |
insulin, igf-1 and glp-1 signaling in neurodegenerative disorders: targets for disease modification? |
2015-01-12 |
2023-08-12 |
Not clear |
| Fares Bassil, Pierre-Olivier Fernagut, Erwan Bezard, Wassilios G Meissne. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Progress in neurobiology. vol 118. 2015-01-12. PMID:24582776. |
these studies have shown that administration of insulin, igf-1 and glp-1 agonists reverses signaling abnormalities and has positive effects on surrogate markers of neurodegeneration and behavioral outcomes. |
2015-01-12 |
2023-08-12 |
Not clear |
| Andres Digenio, Sudeep Karve, Sean D Candrilli, Mehul Dala. Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting. Postgraduate medicine. vol 126. issue 6. 2015-01-12. PMID:25414934. |
the objective of the current study was to document the characteristics and clinical outcomes of patients with t2dm initiating prandial insulin or a glucagon-like peptide-1 (glp-1) receptor agonist while on basal insulin. |
2015-01-12 |
2023-08-13 |
Not clear |
| Nadia M Krasner, Yasuo Ido, Neil B Ruderman, Jose M Caciced. Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PloS one. vol 9. issue 5. 2015-01-10. PMID:24835252. |
similar to the actions of endogenous glp-1, liraglutide potentiates the post-prandial release of insulin, inhibits glucagon release and increases satiety. |
2015-01-10 |
2023-08-13 |
human |
| Tae-Young Ha, Young-Seok Kim, Chun Hwa Kim, Hyo-Sun Choi, Jin Yang, Soo Hyun Park, Dae Hoon Kim, Jae-Keol Rhe. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus. Archives of pharmacal research. vol 37. issue 5. 2015-01-05. PMID:23897163. |
it is predominantly expressed in pancreatic β-cells, directly promotes glucose stimulated insulin secretion and indirectly increases glucagon-like peptide 1 (glp-1) levels reducing appetite and food intake. |
2015-01-05 |
2023-08-12 |
mouse |
| Tae-Young Ha, Young-Seok Kim, Chun Hwa Kim, Hyo-Sun Choi, Jin Yang, Soo Hyun Park, Dae Hoon Kim, Jae-Keol Rhe. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus. Archives of pharmacal research. vol 37. issue 5. 2015-01-05. PMID:23897163. |
insulin and glp-1 level were increased in a dose-dependent manner. |
2015-01-05 |
2023-08-12 |
mouse |
| Katsunori Nonogaki, Miki Hazama, Noriko Sato. Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice. BioMed research international. vol 2014. 2015-01-05. PMID:24804243. |
here we show that systemic administration of liraglutide, a long-acting human glucagon-like peptide-1 (glp-1) analog, significantly decreased food intake, body weight, and blood glucose levels at 24 h after its administration while having no significant effects on plasma insulin and glucagon levels in individually housed kka(y) mice. |
2015-01-05 |
2023-08-13 |
mouse |
| Katsunori Nonogaki, Miki Hazama, Noriko Sato. Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice. BioMed research international. vol 2014. 2015-01-05. PMID:24804243. |
these findings suggest that systemic administration of liraglutide induces hepatic fgf21 production and suppresses the social isolation-induced obesity and diabetes independently of insulin, glucagon, and active glp-1 in kka(y) mice. |
2015-01-05 |
2023-08-13 |
mouse |
| Changrun Guo, Chunfeng Zhang, Lu Li, Zhenzhong Wang, Wei Xiao, Zhonglin Yan. Hypoglycemic and hypolipidemic effects of oxymatrine in high-fat diet and streptozotocin-induced diabetic rats. Phytomedicine : international journal of phytotherapy and phytopharmacology. vol 21. issue 6. 2015-01-02. PMID:24680614. |
the results demonstrated that oxymatrine could significantly decrease fasting blood glucose, glycosylated hemoglobin (ghb), food and water intake, non-esterified fatty acid (nefa), total cholesterol (tc), triglyceride (tg), low density lipoprotein cholesterol levels (ldl-c), and increase serum insulin, liver and muscle glycogen, high density lipoprotein cholesterol (hdl-c), glucagon-like peptide-1 (glp-1) and muscle glucose transporter-4 (glut-4) content in diabetic rats. |
2015-01-02 |
2023-08-12 |
rat |
| Yoshitaka Kihira, Mariko Miyake, Manami Hirata, Yoji Hoshina, Kana Kato, Hitoshi Shirakawa, Hiroshi Sakaue, Noriko Yamano, Yuki Izawa-Ishizawa, Keisuke Ishizawa, Yasumasa Ikeda, Koichiro Tsuchiya, Toshiaki Tamaki, Shuhei Tomit. Deletion of hypoxia-inducible factor-1α in adipocytes enhances glucagon-like peptide-1 secretion and reduces adipose tissue inflammation. PloS one. vol 9. issue 4. 2015-01-02. PMID:24705496. |
our results suggest that the deletion of hif-1α in adipocytes improves glucose tolerance by enhancing insulin secretion through the glp-1 pathway and by reducing macrophage infiltration and inflammation in adipose tissue. |
2015-01-02 |
2023-08-13 |
mouse |
| Manuel Gil-Lozano, Erli L Mingomataj, W Kelly Wu, Sean A Ridout, Patricia L Brubake. Circadian secretion of the intestinal hormone GLP-1 by the rodent L cell. Diabetes. vol 63. issue 11. 2014-12-30. PMID:24789917. |
this profile of glp-1 release correlated with the pattern in insulin secretion, and both rhythms were completely inverted in animals subjected to a 12-h feeding cycle disruption and abolished in rats maintained under constant light conditions. |
2014-12-30 |
2023-08-13 |
rat |
| Manuel Gil-Lozano, Erli L Mingomataj, W Kelly Wu, Sean A Ridout, Patricia L Brubake. Circadian secretion of the intestinal hormone GLP-1 by the rodent L cell. Diabetes. vol 63. issue 11. 2014-12-30. PMID:24789917. |
a daily variation in the insulin response to exogenous glp-1 was also found. |
2014-12-30 |
2023-08-13 |
rat |
| Ajay Kuma. Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy. Expert opinion on biological therapy. vol 14. issue 6. 2014-12-29. PMID:24702171. |
insulin degludec/liraglutide (ideglira) is a once-daily fixed-dose combination of ultra-long-acting basal insulin degludec (ideg) and glp-1 ra, liraglutide. |
2014-12-29 |
2023-08-13 |
Not clear |
| José C Fernández-García, Mora Murri, Leticia Coin-Aragüez, Juan Alcaide, Rajaa El Bekay, Francisco J Tinahone. GLP-1 and peptide YY secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects. Clinical endocrinology. vol 80. issue 5. 2014-12-18. PMID:23573808. |
glp-1 and peptide yy secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects. |
2014-12-18 |
2023-08-12 |
human |